A cancer-killing virus that City of Hope scientists developed could one day improve the immune system's ability to eradicate tumors in colon cancer patients, according to a study in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
University of Virginia Cancer Center researchers have identified a gene responsible for the spread of triple-negative breast cancer to other parts of the body, and developed a potential way to stop it.
City of Hope has initiated a phase I clinical trial that will test one of its investigational SARS-CoV-2 vaccines in healthy volunteers between the ages of 18 and 55 who have not had COVID-19.
A new paper published in JNCI: Journal of the National Cancer Institute indicates that receiving assisted reproductive technology does not increase the risk women have for developing ovarian cancer.
Researchers at the UCLA Jonsson Comprehensive Cancer Center found patients with a particular type of human leukocyte antigen (HLA), a protein scaffold involved in presenting pieces of proteins described as peptides to the immune system, were particularly likely to benefit from immunotherapy.
Researchers at NYU Grossman School of Medicine and Perlmutter Cancer Center trained a computer to tell which skin cancer patients may benefit from drugs that keep tumors from shutting down the immune system's attack on them.
Phase III trial data shows that a developmental drug, plinabulin, could help keep cancer patients on needed chemotherapy treatments.
Nerlynx (neratinib) demonstrates a 5.1% invasive disease-free survival benefit versus placebo in the phase III ExteNET trial evaluating Nerlynx in HER2-positive, hormone receptor-positive early stage breast cancer.
In a phase III trial, Keytruda (pembrolizumab) plus Lenvima (lenvatinib) met the primary endpoint of progression-free survival as first-line treatment of advanced renal cell carcinoma.
In a phase IIb study, Tavo (tavokinogene telseplasmid) in combination with Keytruda (pembrolizumab) led to a 30% overall response rate in the first 54 out of 100 planned patients who have rigorously defined anti-PD1 checkpoint resistant metastatic melanoma.
